AUG 05, 2020 12:08 PM PDT

A New Test to Analyze Cell-Free DNA in Cancer Diagnostics

WRITTEN BY: Jasper Cantrell

Cell-free DNA (cfDNA) are small pieces of genomic DNA that have escaped into the bloodstream either through active release by the cell or are remnants of a terminated cell. In recent years, identification and profiling of cfDNA by size was found to be an early indicator of early-stage cancers. Cancer has a higher ratio of small/large cfDNA than normal cfDNA profiles, which could be seen in tests.

Current methods of analyzing cfDNA in the blood suffer from some issues. Samples are often contaminated with genomic DNA from cells accidentally lysed during handling. Contaminating DNA degrading enzymes can also affect cfDNA levels in a sample. On top of it all, cfDNA is not abundant in the blood, so enrichment is needed before testing can be done.

A team from Simon Fraser University in Canada developed a possible method to overcome these downfalls of current cfDNA analysis methods. They would use droplet digital PCR, which combines PCR (which is used to amplify the cfDNA signal so it can be analyzed) with droplet formation (which is used to get many tests from one sample).

They started with 117 samples from patients with and without cancer. To determine the size profile, they used primers targeted for specific marker genes with known sizes alongside an internal control. They then compared the results of the droplet digital PCR test with the current tests to measure accuracy. Their assay’s results were in line with the current methodology. They observed that samples from cancer patients had a higher ratio of small/medium cfDNA fragments compared to samples from healthy patients.

To counter the possible genomic DNA contamination, the team utilized a profiling method of separating cfDNA into three sizes; small, medium, and large. Genomic DNA is often far larger than the short or medium, so a ratio of small/medium cfDNA was used to determine if a sample had higher DNA fragmentation than normal. They note that although cutting out the larger DNA fragments made the test resistant to genomic DNA contamination, to much genomic DNA could still interfere with the results.

This digital droplet PCR assay uses a small amount of cfDNA to generate analyzable datasets. The profiling method used by this assay is simple and is resistant to contaminating genomic DNA. The team also found that a high small/medium cfDNA ratio seems to be indicative of cancer, which is in line with many other studies. Unfortunately, the team notes that any mutations in the marker genes used in this test could ruin test results.

The study concludes, “Taken together, our data show that assays inferring ctDNA levels from cfDNA size distributions are a convenient approach to identify candidate samples with high ctDNA but these measurements must be always corroborated by complementary methods.”

Sources: Nature Scientific Reports, NEJMvideo

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 13, 2020
Cancer
Predictive model assesses risk of adverse side effects for chemotherapy patients
NOV 13, 2020
Predictive model assesses risk of adverse side effects for chemotherapy patients
New research published in npj Systems Biology and Applications showcases a model capable of predicting which patien ...
NOV 23, 2020
Cancer
Women show higher survival rates than men post lung cancer surgery
NOV 23, 2020
Women show higher survival rates than men post lung cancer surgery
New research published in the journal Chest shows that women fare better than men following lung cancer surgery. Th ...
DEC 07, 2020
Cancer
Black women with breast cancer have higher rates of mortality and comorbidities
DEC 07, 2020
Black women with breast cancer have higher rates of mortality and comorbidities
New research published today the American Cancer Society’s peer-reviewed journal, Cancer, looks at the mortality r ...
DEC 09, 2020
Cancer
Fertility after breast cancer
DEC 09, 2020
Fertility after breast cancer
New data presented at the 2020 San Antonio Breast Cancer Symposium this week dives into the complexities of fertility af ...
JAN 11, 2021
Cancer
Sentinel Nodes Could Reveal a Tumor's Prognosis
JAN 11, 2021
Sentinel Nodes Could Reveal a Tumor's Prognosis
For many diseases, the ability to quickly and effectively diagnose or prognose a patient is critical. If caught early on ...
Loading Comments...